Related references
Note: Only part of the references are listed.Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
Ekkehard Moessner et al.
BLOOD (2010)
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
Stephen A. Beers et al.
BLOOD (2010)
Anti-CD20 monoclonal antibodies: historical and future perspectives
Sean H. Lim et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies
Gadi Gazit Bornstein et al.
INVESTIGATIONAL NEW DRUGS (2010)
Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
M. Hallek et al.
LANCET (2010)
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody
David M. Goldenberg et al.
BLOOD (2009)
An Imaging-Based Rapid Evaluation Method for Complement-Dependent Cytotoxicity Discriminated Clinical Response to Rituximab-Containing Chemotherapy
Yuji Mishima et al.
CLINICAL CANCER RESEARCH (2009)
Variable Contribution of Monoclonal Antibodies to ADCC in patients with chronic lymphocytic leukemia
James Weitzman et al.
LEUKEMIA & LYMPHOMA (2009)
A decade of rituximab: Improving survival outcomes in non-Hodgkin's lymphoma
Arturo Molina
ANNUAL REVIEW OF MEDICINE (2008)
Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation
Stephen A. Beers et al.
BLOOD (2008)
Lenalidomide down-regulates the CD20 antigen and antagonizes direct and antibody-dependent cellular cytotoxicity of rituximab on primary chronic lymphocytic leukemia cells
Rosa Lapalombella et al.
BLOOD (2008)
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Laura Z. Rassenti et al.
BLOOD (2008)
The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVHgenes
Aditya Veldurthy et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype:: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients
Constantine S. Tam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16
Christophe de Romeuf et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies
Ronald P. Taylor et al.
CURRENT OPINION IN IMMUNOLOGY (2008)
Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
Clive S. Zent et al.
LEUKEMIA RESEARCH (2008)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
Julie A. Bowles et al.
BLOOD (2006)
Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: Mechanism of anti body-dependent cellular cytotoxicity and impact of human serum
Marie-Laure Lefebvre et al.
JOURNAL OF IMMUNOTHERAPY (2006)
Modulation of therapeutic antibody effector functions by glycosylation engineering:: Influence of Golgi enzyme localization domain and co-expression of heterologous β1,4-N-acetylglucosaminyltransferase III and Golgi α-mannosidase II
C Ferrara et al.
BIOTECHNOLOGY AND BIOENGINEERING (2006)
High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G
S Preithner et al.
MOLECULAR IMMUNOLOGY (2006)
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
MJ Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
SS Farag et al.
BLOOD (2004)
Rituximab and alemtuzumab induce a nonclassic, caspase-independent apoptotic pathway in B-lymphoid cell lines and in chronic lymphocytic leukemia cells
M Stanglmaier et al.
ANNALS OF HEMATOLOGY (2004)
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg et al.
BLOOD (2003)
Rapamycin-induced G(1) arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin
T Decker et al.
BLOOD (2003)
Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)
JC Byrd et al.
BLOOD (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species
B Bellosillo et al.
BLOOD (2001)
Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
D Huhn et al.
BLOOD (2001)
Share Paper
